logo
  

Kellogg Expects 2018 Adj. EPS Growth Of 9%-11%

Kellogg Co. (K) said it expects that on a currency-neutral basis, adjusted earnings per share growth of 9%-11%, flat net sales on a currency-neutral basis, and operating profit growth of 4%-6% for 2018.

"We enter 2018 on sound financial footing, with many of our businesses starting to gain traction. net sales guidance for 2018 reflects roughly two quarters of negative DSD-transition impacts and the prudent assumption that it will take some time for our investments to take hold. Our commercial ideas are stronger, and we are putting increased investment where the growth is. We have strong enough cost-savings that we can boost investment in growth, while still delivering margin expansion and solid growth in profit and earnings." said Steve Cahillane, Kellogg Company's Chief Executive Officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT